Skip to search boxSkip to navigationSkip to main content

Methylglyoxal-bovine serum albumin stimulates tumor necrosis factor alpha secretion in RAW 264.7 cells through activation of mitogen-activating protein kinase, nuclear factor κB and intracellular reactive oxygen species formation

  • ,
  • R. Subramaniam
    ,
  • M. F. Weiss
    ,
  • V. M. Monnier(corresponding author)
*Corresponding author for this work
  • Case Western Reserve University
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Accumulating evidence suggests that the pathophysiology of diabetes is analogous to chronic inflammatory states. Circulating levels of inflammatory cytokines such as IL-6 and tumor necrosis factor alpha (TNFα) are increased in both type 1 and type 2 diabetes. TNFα plays an important role in the pathogenesis of insulin resistance in type 2 diabetes. However, the reason for this increase remains unclear. Levels of the dicarbonyl methylglyoxal (MGO) are elevated in diabetic plasma and MGO-modified bovine serum albumin (MGO-BSA) can trigger cellular uptake of TNF. Therefore we tested the hypothesis that MGO-modified proteins may cause TNFα secretion in macrophage-like RAW 264.7 cells. Treatment of cells with MGO-BSA induced TNFα release in a dose-dependent manner. MGO-modified ribonuclease A and chicken egg ovalbumin had similar effects. Cotreatment of cells with antioxidant reagent N-acetylcysteine (NAC) inhibited MGO-BSA-induced TNFα secretion. MGO-BSA stimulated the simultaneous activation of p44/42 and p38 mitogen-activated protein kinase. PD98059, a selective MEK inhibitor, inhibited MGO-BSA-induced TNFα release as well as ERK phosphorylation. Pretreatment of cells with NAC also resulted in inhibition of MGO-BSA-induced ERK phosphorylation. MGO-BSA induced dose-dependent NFκB activation as shown by electrophoresis mobility shift assay. The MGO-BSA-induced NFκB activation was prevented in the presence of PD98059, NAC, and parthenolide, a selective inhibitor of NFκB. Furthermore, the NFκB inhibitor parthenolide suppressed MGO-BSA-induced TNFα secretion. Confocal microscopy using dichlorofluorescein to demonstrate intracellular reactive oxygen species (ROS) showed that MGO-BSA produced more ROS compared with native BSA. MGO-BSA could also stimulate protein kinase C (PKC) translocation to the cell membrane, considered a key signaling pathway in diabetes. However, there was no evidence that PKC was involved in TNFα release based on inhibition by calphostin C and staurosporine. Our findings suggest that the presence of chronically elevated levels of MGO-modified bovine serum albumin may contribute to elevated levels of TNFα in diabetes.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 274-286 (13 pages)

Journal (Volume, Issue Number)

Archives of Biochemistry and Biophysics (Volume 409, Issue 2)

Publication milestones

  • Published - 01/15/2003

Publication status

Published - 01/15/2003

ISSN

0003-9861

Publication IDs

  • Scopus: 0037440425
  • PubMed: 12504894

Publication metrics

Metrics

SciVal
FWCI
2.08
SciVal
Author count
4
SciVal
citations
71
SciVal
Paper percentile
90
SciVal
Top percentile
10
Fractional count
1
Fractional count
0.25
Fractional count
3
Fractional count
0.75
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Captures
40
Citation count
82

Funding Details

This study was supported by a generous grant from Taisho Pharmaceutical Co., a mentorship grant from the American Diabetes Association, and NIDDK DK 45619 (to M.F. Weiss), and in part by DK 9900020 (to V.M.M. and M.F.W.). R. Subramaniam was a Fellow of the Juvenile Diabetes Research Foundation
FundersFunding numbers
ADA
-
NIDDK
DK 9900020, R01DK045619
Taiho Pharmaceutical Co., Ltd.
-